Prevalence of appropriate cardioverter-defibrillator shocks in 1038 consecutive patients with implantable cardioverter-defibrillators

American Journal of Therapeutics

Volumn 16, Issue 4, 2009, Pages 323-325

  Kruger, Adam ^a   Aronow, Wilbert S ^a   Lai, Hoang ^a   Desai, Harit ^a   Singla, Atul ^a   Frishman, William H ^a   Cohen, Martin ^a   Sorbera, Carmine ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Amiodarone; B blockers; Cardioverter defibrillator shocks; Implantable cardioverter defibrillators; Sotalol

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; SOTALOL;

AGED; ARTICLE; CARDIOGENIC SHOCK; CARDIOVERTER DEFIBRILLATOR SHOCK; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEFIBRILLATOR; FEMALE; FOLLOW UP; HEART MUSCLE ISCHEMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; LONG QT SYNDROME; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SUDDEN DEATH; SYNCOPE;

ADRENERGIC BETA-ANTAGONISTS; AGE FACTORS; AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; DEFIBRILLATORS, IMPLANTABLE; DRUG THERAPY, COMBINATION; ELECTRIC COUNTERSHOCK; EQUIPMENT FAILURE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; SEX FACTORS; SOTALOL; TREATMENT OUTCOME;

EID: 68049088413     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181727a59     Document Type: Article

References (6)

1. Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/NASPE 2002 guideline uptake for implantation of cardiac pacemakers and antiarrhythmia devices: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to update the 1998 Pacemaker Guidelines). Circulation. 2002;106:2145-2161.
2. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult-summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation. Endorsed by the Heart Rhythm Society. J Am Coll Cardiol. 2005;46:1116-1143.
3. Tandri H, Griffith LS, Tang T, et al. Clinical course and long-term follow-up of patients receiving implantable cardioverter-defibrillators. Heart Rhythm. 2006;3:762-768.
4. Singh JP, Hall WJ, McNitt S, et al. Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia /fibrillation. Findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II). J Am Coll Cardiol. 2005;46:1712-1720.
5. Ellenbogen KA, Levine JH, Berger RD, et al. Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy? Circulation. 2006;113:776-782.
6. Chen HA, Hsia HH, Vagelos R, et al. The effect of gender on mortality or appropriate shock in patients with nonischemic cardiomyopathy who have implantable cardioverter-defibrillators. Pacing Clin Electrophysiol. 2007;30:390-394.